Abstract
Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies investigating its pharmacokinetics (PK) and safety have been performed in this vulnerable population. We review five phase I studies examining the PK of fluconazole in premature infants, which demonstrate markedly differing kinetics compared to adults. Based on these data, a treatment dose of 12mg/kg/day, with the potential need of a loading dose of 25mg/kg to achieve rapid steady state concentrations, achieves surrogate pharmacodynamic targets. Additionally, fluconazole appears to be safe to use in this population, with only minimal reversible hepatobiliary effects.
Keywords: Fluconazole, infant, premature, preterm, safety, pharmacokinetics, candida, infection, treatment, neonate.
Current Medicinal Chemistry
Title:Fluconazole Pharmacokinetics and Safety in Premature Infants
Volume: 19 Issue: 27
Author(s): K. Turner, P. Manzoni, D. K. Benjamin, M. Cohen-Wolkowiez, P. B. Smith and M. M. Laughon
Affiliation:
Keywords: Fluconazole, infant, premature, preterm, safety, pharmacokinetics, candida, infection, treatment, neonate.
Abstract: Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies investigating its pharmacokinetics (PK) and safety have been performed in this vulnerable population. We review five phase I studies examining the PK of fluconazole in premature infants, which demonstrate markedly differing kinetics compared to adults. Based on these data, a treatment dose of 12mg/kg/day, with the potential need of a loading dose of 25mg/kg to achieve rapid steady state concentrations, achieves surrogate pharmacodynamic targets. Additionally, fluconazole appears to be safe to use in this population, with only minimal reversible hepatobiliary effects.
Export Options
About this article
Cite this article as:
Turner K., Manzoni P., K. Benjamin D., Cohen-Wolkowiez M., B. Smith P. and M. Laughon M., Fluconazole Pharmacokinetics and Safety in Premature Infants, Current Medicinal Chemistry 2012; 19 (27) . https://dx.doi.org/10.2174/092986712803306367
DOI https://dx.doi.org/10.2174/092986712803306367 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients
Current Pharmaceutical Biotechnology AIDS-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (HAART)
Current HIV Research Cerebral Collateral Circulation in Carotid Artery Disease
Current Cardiology Reviews Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research The Causative Organisms of Bacterial Meningitis and their Antimicrobial Resistance Profiles in Iranian Children in 2011-2016
Infectious Disorders - Drug Targets Treating Schizophrenia: Novel Targets for the Cholinergic System
CNS & Neurological Disorders - Drug Targets Prokaryotic Substrate-Binding Proteins as Targets for Antimicrobial Therapies
Current Drug Targets Clinical Trials with Intracerebral Convection-Enhanced Delivery of Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials Clinical Pharmacology of Current and Future Drugs for the Acute Treatment of Migraine: A Review and An Update
Current Clinical Pharmacology Usefulness of Real-Time PCR for the Diagnosis of Sepsis in ICU-Acquired Infections
Infectious Disorders - Drug Targets The Use of Interferon-Gamma Therapy in Chronic Granulomatous Disease
Recent Patents on Anti-Infective Drug Discovery Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design The Role of Macrophage Migration Inhibitory Factor in Critical Illness
Mini-Reviews in Medicinal Chemistry Polymorphic Receptors of the Innate Immune System (MBL/MASP-2 and TLR2/4) and Susceptibility to Pneumococcal Bacteremia in HIV-Infected Patients: A Case-Control Study
Current HIV Research Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps
Current Medicinal Chemistry Therapeutic Modulation of Cytokines in Chronic Infectious Diseases
Current Pharmaceutical Design Advancement in Nanoparticle-based Biosensors for Point-of-care <i>In vitro</i> Diagnostics
Current Topics in Medicinal Chemistry